Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 10770 Wateridge Circle Suite 200 Suite 200 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.maravai.com |
IR: | See website |
Key People | ||
Carl W. Hull Executive Chairman of the Board | William Martin Chief Executive Officer | Kevin M. Herde Chief Financial Officer |
Peter Michael Leddy Executive Vice President, Chief Administrative Officer | Kurt Oreshack General Counsel, Secretary | Christine Dolan Chief Operating Officer - Biologics Safety Testing |
Business Overview |
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. |
Financial Overview |
For the fiscal year ended 31 December 2023, Maravai Lifesciences Holdings Inc revenues decreased 67% to $288.9M. Net loss totaled $119M vs. income of $220.2M. Revenues reflect Nucleic Acid Production segment decrease of 72% to $224.8M, Biologics Safety Testing segment decrease of 8% to $64.2M, Europe, the Middle East and Africa segment decrease of 88% to $49.9M, North America segment decrease of 58% to $141.1M. |
Employees: | 650 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,925M as of Dec 31, 2023 |
Annual revenue (TTM): | $288.95M as of Dec 31, 2023 |
EBITDA (TTM): | $33.92M as of Dec 31, 2023 |
Net annual income (TTM): | -$119.03M as of Dec 31, 2023 |
Free cash flow (TTM): | $60.67M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 251,399,871 as of Feb 21, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |